Zanidatamab Plus Chemotherapy Prolongs PFS Over Trastuzumab Plus Chemotherapy in Patients with HER2-positive Advanced Gastro-Oesophageal Adenocarcinoma By Ogkologos - June 1, 2026 173 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the HERIZON-GEA-01 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Penn State Researchers Working on Amazon Alexa Skill for Metastatic Breast... May 4, 2021 Changes to chromosomes impact how children’s brain tumours respond to treatment November 4, 2022 Woman with Strong Family History of Cancer Finally Gets Diagnosis After... November 4, 2020 The Childhood Cancer Data Initiative: Why Data Sharing Is Essential to... June 12, 2019 Load more HOT NEWS European Lung Cancer Congress 2025, Paris, France, 26-29 March 2025 FDA Approves Cabozantinib for Differentiated Thyroid Cancer New tool to tackle gaps in public’s knowledge of blood cancer... Largest Study on Frequent Aspirin Use Supports Reduction in Ovarian Cancer...
